TARS240517P22500
- 0.50
- 0.000.00%
Tarsus Pharmaceuticals Newsroom
12 Health Care Stocks Moving In Monday's Pre-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INK
Analysts Are Betting On Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) With A Big Upgrade This Week
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply increased
Express News | Tarsus Pharmaceuticals, Inc. : H.c. Wainwright Raises Target Price to $61 From $57
Express News | Tarsus Pharmaceuticals Inc : Jefferies Raises Target Price to $48 From $46
Tarsus Pharmaceuticals Is Maintained at Overweight by Barclays
Tarsus Pharmaceuticals Is Maintained at Overweight by Barclays
Express News | Barclays Maintains Overweight on Tarsus Pharmaceuticals, Raises Price Target to $60
Express News | Tarsus Pharmaceuticals : Barclays Raises Target Price to $60 From $50
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA)
Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients,
Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Tarsus Pharmaceuticals Is Maintained at Outperform by Oppenheimer
Tarsus Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 43.16% Oppenheimer $59 → $61 Maintains Outperform 03/06/2024 3.26% Jefferies $30 → $44 Maintain
Earnings Call Summary | Tarsus Pharmaceuticals(TARS.US) Q1 2024 Earnings Conference
The following is a summary of the Tarsus Pharmaceuticals, Inc. (TARS) Q1 2024 Earnings Call Transcript:Financial Performance:Tarsus reported $27.6 million in total revenue, made up of $24.7 million in
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating
Tarsus Pharmaceuticals (TARS) has an average rating of Buy and price targets ranging from $30 to $67, according to analysts polled by Capital IQ. Price: 35.83, Change: -1.52, Percent Change: -4.07
Top 5 Health Care Stocks That Could Sink Your Portfolio In Q2
As of May 9, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator,
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersZai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings
Express News | Tarsus Pharmaceuticals Inc : Guggenheim Raises Target Price to $67 From $60
Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ...
Tarsus Pharmaceuticals | 10-Q: Quarterly report
Express News | Tarsus Pharmaceuticals Inc Q1 Shr View $-1.20, Rev View $17.5 Mln -- Lseg Ibes Data
Express News | Tarsus Pharmaceuticals Inc: Qtrly Shr Loss $1.01